Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial

International Journal of Urology

Volumn 18, Issue 5, 2011, Pages 365-373

  Gotoh, Momokazu ^a   Yokoyama, Osamu ^b   Nishizawa, Osamu ^c  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Japanese; Overactive bladder; Placebo; Propiverine hydrochloride; Randomized controlled trial

Indexed keywords

PROPIVERINE;

ADULT; ARTICLE; BLURRED VISION; CONSTIPATION; CONTROLLED STUDY; DETRUSOR MUSCLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; URINARY HESITANCY; URINE INCONTINENCE; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BENZILATES; CHOLINERGIC ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINATION; URINE; YOUNG ADULT;

EID: 79955113064     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02732.x     Document Type: Article

References (18)

1. Abrams P, Cardozo L, Fall M etal. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol. Urodyn. 2002; 21: 167-78.
2. Homma Y, Yamaguchi O, Hayashi K; Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int. 2005; 96: 1314-18.
3. Tokuno H, Chowdhury JU, Tomita T. Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle. Naunyn. Schmiedebergs Arch. Pharmacol. 1993; 348: 659-62.
4. Haruno A, Yamasaki Y, Miyoshi K etal. Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder. Nippon Yakurigaku Zasshi 1989; 94: 145-50.
5. Lee KS, Lee HW, Choo MS etal. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the "Propiverine study on overactive bladder including urgency data". BJU Int. 2010; 105: 1565-70.
6. Jünemann KP, Hessdörfer E, Unamba-Oparah I etal. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol. Int. 2006; 77: 334-9.
7. Dorschner W, Stolzenburg JU, Griebenow R etal. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur. Urol. 2000; 37: 702-8.
8. Homma Y, Yamaguchi O, Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int. J. Urol. 2009; 16: 499-506.
9. Yamaguchi O, Marui E, Kakizaki H etal.; Japanese Solifenacin Study Group. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int. 2007; 100: 579-87.
10. Homma Y, Yoshida M, Seki N etal. Symptom assessment tool for overactive bladder syndrome: overactive bladder symptom score. Urology 2006; 68: 318-23.
11. Homma Y, Gotoh M, Ando T, Fukuhara S. Development of Japanese version of QOL questionnaires for urinary incontinence. J. Neurogen. Bladder Soc. 1999; 10: 225-36.
12. Matsushima S, Inada H, Asai T, Naka M, Tanaka T. Propiverine hydrochloride, an anti-pollakiuric agent, inhibits the activity of actomyosin ATPase from the urinary bladder. Eur. J. Pharmacol. 1997; 333: 93-7.
13. + transients in murine urinary bladder myocytes. J. Pharmacol. Exp. Ther. 2008; 324: 118-27.
14. Yoshida M, Homma Y, Inadome A etal. Age-related changes in cholinergic and purinergic neurotransmission in human isolated bladder smooth muscles. Exp. Gerontol. 2001; 36: 99-109.
15. Yono M, Yoshida M, Wada Y etal. Pharmacological effects of tolterodine on human isolated urinary bladder. Eur. J. Pharmacol. 1999; 368: 223-30.
16. Ito K, Nishi T. Long-term administration study of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence. Jpn Pharmacol. Ther. 2002; 30: 37-47.
17. Stöhrer M, Madersbacher H, Richter R etal. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial. Spinal Cord 1999; 37: 196-200.
18. Jünemann K, Halaskab M, Rittsteinc T etal. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur. Urol. 2005; 48: 478-82.